This website is intended for Medical Professionals only. By using this site you confirm that you are a healthcare professional.

News
Maar Dora Francesco Carelli, University of Milan (12 Dec 2019)
Anastrozole reduces breast cancer rates for ... Queen Mary University of London-led research finds Anastrozole ... (10 Dec 2019)
Taking fish oil tablets for four weeks ... Fish oil supplements can significantly improve ‘night vision’, ... (12 Dec 2019)
Give a Gift this Christmas which gives back The story of medicine is the story of civilization, from an ... (12 Dec 2019)
Elderly people should aim to keep up step ... Just two weeks of inactivity increases body fat and harms ... (12 Dec 2019)
×

Warning

JUser: :_load: Unable to load user with ID: 5232
Monday, 22 August 2016 00:00

The Pharmacokinetics of the Antiviral Agents indicated in Influenza: What Are The Clinical Implications?

Written by
Rate this item
(0 votes)

Abstract

Several of the recent advances in antiviral drug development indicated in influenza have been due to the improved pharmacokinetic properties of the drugs now available. There are four licensed influenza antiviral agents which are now available. Amantadine, rimantadine, and oseltamivir are administered orally, while zanamir is given as a dry powder that is self-administered via oral inhalation. This brief review summarises how the four drugs differ in terms of their pharmacokinetics, and how this knowledge may help to predict drug interactions and side effects, and estimate dosage adjustments in varying age groups and in patients with underlying pathological conditions.


Introduction


Advances in antiviral drug development and in rapid diagnostic methods have resulted in more efficient management strategies in the treatment of influenza.1 Several of these advances have been particularly due to the improved pharmacokinetic properties of the drugs now available. 2

Four licensed antiviral agents indicated in influenza are now available: the adamantanes (amantadine and rimantadine) with activity against influenza A viruses but not influenza B viruses; and the newer class of neuraminidase inhibitors (zanamivir [Relenza®] and oseltamivir [Tamiflu®]), which have activity against both influenza A and B viruses.3

The Adamantanes : Amantadine and Rimantadine

Amantidine is the oldest drug in this group having being marketed since 1966. Approximately 90% of amantadine is excreted unchanged in the urine by glomerular filtration and tubular secretion.4 On the other hand, approximately 75% of rimantadine is metabolized by the liver and the apparent clearance of rimantadine has been found to be 50% lower for persons with severe liver dysfunction.5 Rimantadine and its metabolites are then excreted by the kidneys.

Reduction in doses with amantadine and rimantadine are thus recommended in patients with any degree of renal insufficiency, but no reduction in dosage is recommended on the basis of age alone.6

The Neuraminidase Inhibitors: Zanamivir And Oseltamivir

Although related in terms of their mode of pharmacological activity, these two drugs have very varying pharmacokinetic parameters.

Zanamivir shows poor oral bioavailability in human volunteers, and in fact is administered as a dry powder using an oral inhaler. Zanamivir thus becomes highly concentrated in the respiratory tract: 10 to 20 % reaches the lungs, and the rest is deposited in the oropharynx.7   Five to 15 % of the total dose is then absorbed and excreted in the urine, resulting in a relative bioavailability of about 2%, with a half-life of 2.5 to 5.1 hours,8 a feature that is potentially advantageous in situations in which a systemic drug is undesirable.3

This poor bioavailability, however, may be a problem in patients for whom inhalation may be difficult or when it is necessary to deliver the drug to sites of viral replication, as in cases of pneumonic disease.8

Population parameters for zanamivir have been estimated by a nonlinear mixed-effect modeling software program (NONMEM), using a one-compartment model with first-order absorption.9 Formulation and route of administration were found to be the most significant factors affecting the pharmacokinetics of zanamivir. No significant differences in pharmacokinetic parameters were observed when demographic variables, indices of infection, or concurrent medication use were considered in either phase I or phase II population analyses.  Limited data is available regarding the safety and efficacy of zanamivir for patients with impaired renal function.9

Oseltamivir is really the ethyl ester prodrug of the active metabolite, oseltamivir carboxylate (GS4071 or Ro 64-0802).10,11,12 Oseltamivir is efficiently converted to GS4071 after high and consistent site-specific absorption (around 80%) of both capsule and suspension formulations, from the gastrointestinal tract.11,12  This is an advantage of oseltamivir over zanamivir since the former achieves high plasma levels and thus can act outside the respiratory tract.

These studies also indicate that absorption is similar in the proximal and distal small bowel, but reduced from the ascending colon and they support the usefulness of a modified-release product.12 Snell et al., found that the co-administration of various antacids with oseltamivir has no effect on the bioavailability or pharmacokinetics of either oseltamivir or the active metabolite.13

After conversion by hepatic carboxylesterases in the liver to the active metabolite, oseltamivir carboxylate, the latter distributes throughout the body, including the upper and lower respiratory tract.10 Neither compound interacts with cytochrome P450 mixed-function oxidases or glucuronosyltransferases.14

The active metabolite is detectable in plasma within 30 minutes and reaches maximal concentrations after 3 to 4 hours.11 The pharmacokinetic profile of the active metabolite is linear and dose-proportional and it is 3% bound to human plasma proteins. After peak plasma concentrations are attained, its concentration declines with an apparent half-life of 6 to 10 hours.  Steady-state plasma concentrations are achieved within 3 days of twice daily administration, and at a dosage of 75mg twice daily, the steady-state plasma trough concentrations of the active metabolite remain above the minimum inhibitory concentration for all influenza strains tested.11 Exposure to the active metabolite at steady-state is approximately 25% higher in elderly compared with young individuals; however, no dosage adjustment is necessary. The pharmacokinetics in patients with influenza are qualitatively similar to those in healthy young adults

The active metabolite is eliminated through the kidneys by a first-order process as the unchanged drug by glomerular filtration and tubular secretion by an anionic transporter system.10,15  Given these characteristics, its potential for adverse interactions with other drugs appears limited to those arising from competitive inhibition of excretion by the renal tubular epithelial cell anionic transporter.  In patients with renal impairment, metabolite clearance decreases linearly with creatinine clearance.10

Oo et al., assessed the metabolic and excretory capacity of oseltamivir and its active carboxylate metabolite in young children and the results demonstrated that infants as young as one year old can metabolize and excrete oseltamivir efficiently.16

 

Conclusion

This brief review has shown the importance of pharmacokinetics parameters when considering the choice, dosage, duration of therapy and use of influenza antiviral medications. During the decision making process, clinicians should also take into account the patient’s age, weight, renal function, presence of other medical conditions and the potential for interaction with other medications.

No published data is as yet available concerning the safety or efficacy of using combinations of any of these four influenza antiviral drugs. Future investigations may also help to clarify the therapeutic role and pharmacokinetic advantages of novel antiviral drugs and formulations still in the development phase.






References

1. Reusser P. Antiviral therapy: current options and challenges. Schweiz Med Wochenschr 2000 ; 130(4):101-12.

2. Oxford JS, Novelli P, Sefton A, Lambkin R. New millennium antivirals against pandemic and epidemic influenza: the neuraminidase inhibitors. Antivir Chem Chemother 2002; 13(4):205-17.

3. Moscona A. Neuraminidase inhibitors for influenza. N Engl J Med 2005; 353(13):1363-73

4.  Bridges CB, Fukuda K, Uyeki TM, Cox NJ, Singleton JA. Centers for Disease Control and Prevention, Advisory Committee on Immunization Practices. Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2002; 51(RR-3):1-31.

5. Soo W. Adverse effects of rimantadine: summary from clinical trials. J Respir Dis 1989: 10:S26-31.

6. Wintermeyer SM, Nahata MC. Rimantadine: a clinical perspective. Ann Pharmacother 1995; 29:299-310.

7. Cass LMR, Brown J, Pickford M. Pharmacoscintigraphic evaluation of lung deposition of inhaled zanamivir in healthy volunteers. Clin Pharmacokinet 1999; 36(suppl 1):21-31.

8. Efthymiopoulos C, Barrington P, Patel J, Harker A, Hussey EK, Bye A. 1994. Pharmacokinetics of the neuraminidase inhibitor 4-guanidino Neu5Ac2en (GG167) following intravenous, intranasal and inhaled administration in man, abstr. H70, p. 265. In: Abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.

9. Peng AW, Hussey EK, Moore KHA. Population pharmacokinetic analysis of zanamivir in subjects with experimental and naturally occurring influenza: effects of formulation and route of administration. J Clin Pharmacol 2000; 40(3):242-9.

10. Doucette KE, Aoki FY. Oseltamivir: a clinical and pharmacological perspective. Expert Opin Pharmacother 2001; 2(10):1671-83.

11. He G, Massarella J, Aitken M. Pharmacokinetics and safety of the oral neuraminidase inhibitor Ro 640796/GS4104 when administered concurrently with cimetidine or probenecid in healthy subjects [Abstract P17]. J Antimicrob Chemother 1999; 44(suppl A):44.

12. Bardsley-Elliot A, Noble S. Oseltamivir. Drugs 1999; 58:851-60.

13. Snell P, Oo C, Dorr A, Barrett J. Lack of pharmacokinetic interaction between the oral anti-influenza neuraminidase inhibitor prodrug oseltamivir and antacids. Br J Clin Pharmacol 2002; 54(4):372-7.

14. He G, Massarella J, Ward P. Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802. Clin Pharmacokinet 1999; 37(6):471-84.

15. Hill G, Cihlar T, Oo C et al. The anti-influenza drug oseltamivir exhibits low potential to induce pharmacokinetic drug interactions via renal secretion-correlation of in vivo and in vitro studies. Drug Metab Dispos 2002; 30(1):13-9.

16. Oo C, Snell P, Barrett J, Dorr A, Liu B, Wilding I. Pharmacokinetics and delivery of the anti-influenza prodrug oseltamivir to the small intestine and colon using site-specific delivery capsules. Int J Pharm 2003; 257(1-2):297-9.

Additional Info

  • TheSynapse Magazines: 2006
Read 3405 times Last modified on Sunday, 20 November 2016 16:41

TheSynapse Magazines

Highlights

Join

Connect with other Medical Professionals on fb in a closed facebook group

Login

Top
We use cookies to improve our website. By continuing to use this website, you are giving consent to cookies being used. More details…